Platinum Priority – EditorialReferring to the article published on pp. 986–997 of this issueOne Strategy Does Not Fit All: The Era of Personalised Medicine for the Treatment of Male Lower Urinary Tract Symptoms Is upon Us
Referring to the article published on pp. 986–997 of this issue
Section snippets
Conflicts of interest
The authors have no relevant discloser.
References (4)
- et al.
Emerging minimally invasive treatment options for male lower urinary tract symptoms
Eur Urol
(2017) - et al.
Prospective, randomized, double blind, vehicle controlled, multinational, phase 3 clinical trial of the pore forming protein PRX302 for targeted treatment of symptomatic benign prostatic hyperplasia
J Urol
(2016)
There are more references available in the full text version of this article.
Cited by (0)
© 2017 European Association of Urology. Published by Elsevier B.V. All rights reserved.